Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.

Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.

Item
http://www.wikidata.org/entity/Q50506494
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugsTirapazamine: a novel agent targeting hypoxic tumor cellsTirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.Tumor-activated prodrugs--a new approach to cancer therapy.Prospects for bioreductive drug development.Tirapazamine-cisplatin: the synergyCisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatinEnhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase.Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts.Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.Hypoxia signalling in tumour angiogenesis
P2860

Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.

Item
http://www.wikidata.org/entity/Q50506494
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@en
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@nl
type
label
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@en
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@nl
prefLabel
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@en
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P5875
P698
P356
P1433
P1476
Phase II study of the combinat ...... ed non-small-cell lung cancer.
@en
P2093
P304
P31
P356
P433
P478
P577
P5875
P698